Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 394

Results For "THA"

8099 News Found

Dupixent significantly reduced COPD exacerbations in second positive Phase 3 trial
Clinical Trials | November 29, 2023

Dupixent significantly reduced COPD exacerbations in second positive Phase 3 trial

Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease


Roche expands hepatitis diagnostics portfolio
Clinical Trials | November 29, 2023

Roche expands hepatitis diagnostics portfolio

Almost 300 million people globally have chronic hepatitis B


Bayer commits to Veeva Vault CRM and Veeva OpenData globally
News | November 29, 2023

Bayer commits to Veeva Vault CRM and Veeva OpenData globally

Establishes connected software and data foundation for the future with next-generation life sciences CRM and harmonized customer data


Aster to separate its India and GCC businesses to unlock value
News | November 29, 2023

Aster to separate its India and GCC businesses to unlock value

Both the India and GCC entities will be operated by separate dedicated management teams


BrainSpec receives FDA clearance to begin using AI-backed solution for non-invasive brain chemistry measurement
Digitisation | November 28, 2023

BrainSpec receives FDA clearance to begin using AI-backed solution for non-invasive brain chemistry measurement

First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease


GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep
News | November 28, 2023

GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep

Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex


Laurus Labs acquires 87.59% stake in Laurus Bio Private
News | November 25, 2023

Laurus Labs acquires 87.59% stake in Laurus Bio Private

Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders


DxVx plans to make a license-in agreement of OVM-200
News | November 25, 2023

DxVx plans to make a license-in agreement of OVM-200

Final stage in licensing OVM-200 from Oxford Vacmedix in the UK


Lupin receives tentative approval from USFDA for Canagliflozin Tablets
Drug Approval | November 24, 2023

Lupin receives tentative approval from USFDA for Canagliflozin Tablets

Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor